Erythropoiesis-stimulating agents in cancer patients: reflections on safety (Q37960528)

26 August 2017

title

Erythropoiesis-stimulating agents in cancer patients: reflections on safety (English)

1 reference

26 August 2017

Isabelle Wauters

1

1 reference

26 August 2017

Johan Vansteenkiste

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

Expert Review of Clinical Pharmacology

26 August 2017

published in

1 reference

26 August 2017

volume

4

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

467-476

1 reference

Chemotherapy-induced anemia in adults: incidence and treatment

26 August 2017

cites work

1 reference

Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey.

21 January 2018

1 reference

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

21 January 2018

1 reference

Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.

21 January 2018

1 reference

Cloning and expression of the human erythropoietin gene

21 January 2018

1 reference

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

21 January 2018

1 reference

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

21 January 2018

1 reference

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis

21 January 2018

1 reference

The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer.

21 January 2018

1 reference

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature

21 January 2018

1 reference

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

21 January 2018

1 reference

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

21 January 2018

1 reference

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

21 January 2018

1 reference

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.

21 January 2018

1 reference

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

21 January 2018

1 reference

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

21 January 2018

1 reference

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

21 January 2018

1 reference

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

21 January 2018

1 reference

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis

21 January 2018

1 reference

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

21 January 2018

1 reference

Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa

21 January 2018

1 reference

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

21 January 2018

1 reference

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

21 January 2018

1 reference

September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents

21 January 2018

1 reference

Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms

21 January 2018

1 reference

Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events

21 January 2018

1 reference

The erythropoietin receptor in normal and cancer tissues

21 January 2018

1 reference

The non-haematopoietic biological effects of erythropoietin

21 January 2018

1 reference

Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells

21 January 2018

1 reference

Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells

21 January 2018

1 reference

Absence of functional EpoR expression in human tumor cell lines

21 January 2018

1 reference

Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells

21 January 2018

1 reference

Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis

21 January 2018

1 reference

Hypoxia in cancer: significance and impact on clinical outcome

21 January 2018

1 reference

21 January 2018

1 reference

Transfusion in coronary artery bypass grafting is associated with reduced long-term survival

21 January 2018

1 reference

Postoperative red blood cell transfusion and morbid outcome in uncomplicated cardiac surgery patients

21 January 2018

1 reference

A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group

21 January 2018

1 reference

Correlation between perioperative blood transfusion and prognosis of patients subjected to surgery for stage I lung cancer.

21 January 2018

1 reference

Duration of red-cell storage and complications after cardiac surgery

21 January 2018

1 reference

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia

21 January 2018

1 reference

Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?

21 January 2018

1 reference

Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy

21 January 2018

1 reference

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

21 January 2018

1 reference

Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.

21 January 2018

1 reference

Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) : a registry for characterizing anaemia management and outcomes in oncology patients.

21 January 2018

1 reference

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

21 January 2018

1 reference

A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia

21 January 2018

1 reference

Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy

21 January 2018

1 reference

Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.11.22

1 reference

26 August 2017

1 reference